Serum Hepatitis C Virus RNA Levels in Chronic Hepatitis C-Importance for outcome of interferon alfa-2b treatment

References

• Alter M, Margolis H, Krawczynski K, Judson F, Mares A, Alexander J, Hu P, Miller J, Gerber M, Samplinger R, Meeks E, Beach M. for the Sentinental Counties chronic non-A and non-B hepatitis study. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905
   PubMed Web of Science ®Google Scholar
• Farci P, Alter H, Wong D, Miller R, Shih J, Jett B, Purcell R. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104
   PubMed Web of Science ®Google Scholar
• Mattsson L, Sönnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13: 274–278
   PubMedGoogle Scholar
• Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero M, Realdi G. Long-term follow-up of non-A, non-B (type C) posttransfusion-hepatitis. J Hepatol 1992; 16: 273–281
   PubMed Web of Science ®Google Scholar
• Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshisawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell R, Alter H. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675
   PubMed Web of Science ®Google Scholar
• Kuo G, Choo Q, Alter H J, Gitmik G L, Redeker A G, Purcell R H, Miyamura T, Dienstag J L, Alter M J, Stevens C E, Tegtmeier G E, Bonino F, Colombo M, Lee W S, Kuo C, Berger K, Shuster J R, Overby L R, Bradley D W, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–364
   PubMed Web of Science ®Google Scholar
• Van D, er Poel C, Cuypers H, Reesink H, Weiner A, Quan S, Di Nello R, Van Boven J, Winkel I, Mulder-Folkerts D, Exel-Ohlers P, Schaasberg W, Leentvaar-Kuypers A, Polito A, Houghton M, Lelie P. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317–319
   PubMed Web of Science ®Google Scholar
• Mattsson L, Gutierrez R, Dawson G, Lesniewski R, Mushahwar I, Weiland O. Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in Iong-term-studied patients with posttransfusion hepatitis C. Scand J Gastroenterol 1991; 26: 1257–1262
   PubMed Web of Science ®Google Scholar
• Houghton M, Weiner A, Han J, Kuo G, Choo Q-L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 381–388
   PubMed Web of Science ®Google Scholar
• Brillanti S, Garson J, Tuke P, Ring C, Briggs M, Masci C, Miglioli M, Barbara L, Tedder R. Effect of alfa-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J Med Virol 1991; 34: 136–41
   PubMed Web of Science ®Google Scholar
• Yun Z, Lindh G, Weiland O, Johansson B, Sönnerberg A. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. J Med Virol 1993; 39: 57–61
   PubMed Web of Science ®Google Scholar
• Shindo M, Di Bisceglie A, Cheung L, Shih W-K, Cristiano K, Feinstone S, Hoofnagle J. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700–704
   PubMed Web of Science ®Google Scholar
• Weiland O, Zhang Y-Y, Widell A. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993; 25: 25–30
   PubMedGoogle Scholar
• Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–883
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kakumu S, Wakita T, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotype virus. J Hepatol 1992; 16: 293–299
   Google Scholar
• Lau J, Davis G, Kniffen J, Qian K-P, Urdea M, Chan C, Mizokami M, Neuwald P, Wilber J. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–1504
   PubMed Web of Science ®Google Scholar
• Kodali V, Gordon S, Silverman A, Urdea M, Chan C, Wilber J. Levels of hepatitis C virus (HCV) RNA correlate with liver histology but not with mode of transmission. Hepatology 1993; 18, Abstract 97 AASLD
   Web of Science ®Google Scholar
• Martinot-Peignoux M, Marcellin P, Poteau M, Erlinger S, Benhamou J. HCV-RNA quantification and response to interferon treatment in patients with chronic hepatitis C. Hepatology 1993; 18, Abstract 747 AASLD
   Google Scholar
• Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S. Quantification and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993; 18: 1319–1325
   PubMedGoogle Scholar
• Yun Z, Lundeberg J, Johansson B, Hedrum A, Weiland O, Uhlén M, Sönnerborg A. Colorimetric detection of competetive PCR products for quantification of hepatitis C viremia. J Virol Methods 1994; 47: 1–14
   PubMedGoogle Scholar
• Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–679
   PubMed Web of Science ®Google Scholar
• Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun Z-B, Weiland O. High sustained response rate and clearence of viraemia in chronic hepatitis C following treatment with interferon alfa-2b for 60 weeks. Hepatology 1994; 19: 280–285
   PubMed Web of Science ®Google Scholar
• International Group. Acute and chronic hepatitis revisited. Lancet 1977; 2: 914–919
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991; 11: 30–38
   PubMedGoogle Scholar
• Lundeberg J, Wahlberg J, Uhlen M. Rapid colorimetric quantification of PCR-amplified DNA. Biotechniques 1991; 10: 68–75
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545–550
   PubMed Web of Science ®Google Scholar
• Gretch D, Han J, Wilson R, Carithers R, Bush M, Sayers M, Corey L. High titre hepatitis C virus infection is associated with advanced disease stage and resistance to interferon. Hepatology 1993; 18, Abstract 125 AASLD
   Google Scholar
• Reichard O, Glaumann H, Norkrans G, Wejstål R, Frydén A, Schvarcz R, Weiland O. Histological outcome in patients with chronic hepatitis C given a 60 weeks interferon alfa-2b treatment course. Liver 1994; 14, in press
   PubMedGoogle Scholar
• Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, Mishiro S. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74: 2385–2390
   PubMed Web of Science ®Google Scholar
• Nosbaum J, Pol S, Gigou M, Okamoto H, Féray C, Poussin K, Paterlini P, Berthelot P, Mishiro S, Bréchot C. HCV genotype II is associated to liver cirrhosis, cancer and low response to interferon alpha in European patients. Hepatology 1993; 18, Abstract 127 AASLD
   Web of Science ®Google Scholar